Bibliographic Details
| Title: |
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies |
| Authors: |
Audicio, Paola F.1 paudicio@cin.edu.uy, Castellano, Gustavo2 gcas@famaf.unc.edu.ar, Tassano, Marcos R.1, Rezzano, Maria E.1, Fernandez, Marcelo1, Riva, Eloisa3, Robles, Ana1, Cabral, Pablo1, Balter, Henia1, Oliver, Patricia1 |
| Source: |
Applied Radiation & Isotopes. Jul2011, Vol. 69 Issue 7, p924-928. 5p. |
| Subjects: |
Rituximab, Radioimmunotherapy, Lymphomas, Monoclonal antibodies, Radiopharmaceuticals, Radioactive tracers, Monte Carlo method, Radiochemistry |
| Abstract: |
Abstract: Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin''s Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. Monte Carlo simulation showed high doses deposited on a spheroid tumor mass model. This method seems to be an appropriate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical. [Copyright &y& Elsevier] |
|
Copyright of Applied Radiation & Isotopes is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Engineering Source |
